The CMAJ editorial on the Vioxx case and its implications for drug safety1 notes some of the
difficulties inherent in postmarketing surveillance, such as extrapolating conclusions from …

Please report paediatric adverse reactions | Australian Adverse Drug Reactions Bulletin
CHANGE DATABASES Start new search. Enter phrases | keywords ... Search Advanced …

Background: As a first step towards implementing routine screening of safety issues
specifically related to children at the Uppsala Monitoring Centre, this study was performed to …

Adverse drug reactions (ADRs) are an important cause of illness and death (1). Of particular
concern is the alarming lack of ADR data in the paediatric population, which, therefore, limits …

T HERE HAS BEEN SURPRISINGLY LITTLE RESEARCH in the public domain on the long-
term safety and effectiveness of postmarket drugs—drugs that have been approved by …

BACKGROUND The safety of medicines used in children is of considerable public interest,
yet available data to monitor the safety of medicines in children is limited. AIMS To raise …

In May, the Government Reform Committee of the US House of Representatives held a
hearing that explored how drugs with serious safety issues can remain so popular for so …

In North America, adverse drug reactions (ADRs) continue to be a major cause of morbidity,
hospital admission and death (1). The above statement runs counter to the common …

We are writing in response to the article by Egilman and colleagues published in
CMAJ,“Optimizing the data available via Health Canada's clinical information portal.” 1 …

The potential for adverse drug events (ADEs) is greater when a new drug is prescribed soon
after its release onto the market, and rapid uptake can place patients at risk of adverse drug …